Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Preferred Shares (2016 - 2019)

Historic Preferred Shares for STRATA Skin Sciences (SSKN) over the last 6 years, with Q4 2019 value amounting to $1000.0.

  • STRATA Skin Sciences' Preferred Shares changed 0.0% to $1000.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $1000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $1000.0 for FY2019, which is 0.0% changed from last year.
  • Per STRATA Skin Sciences' latest filing, its Preferred Shares stood at $1000.0 for Q4 2019, which was down 0.0% from $1000.0 recorded in Q3 2019.
  • STRATA Skin Sciences' 5-year Preferred Shares high stood at $4000.0 for Q3 2017, and its period low was $1000.0 during Q2 2015.
  • Moreover, its 5-year median value for Preferred Shares was $1000.0 (2015), whereas its average is $1529.4.
  • Per our database at Business Quant, STRATA Skin Sciences' Preferred Shares surged by 30000.0% in 2017 and then plummeted by 7500.0% in 2018.
  • Quarter analysis of 5 years shows STRATA Skin Sciences' Preferred Shares stood at $1000.0 in 2015, then changed by 0.0% to $1000.0 in 2016, then soared by 300.0% to $4000.0 in 2017, then crashed by 75.0% to $1000.0 in 2018, then changed by 0.0% to $1000.0 in 2019.
  • Its Preferred Shares was $1000.0 in Q4 2019, compared to $1000.0 in Q3 2019 and $1000.0 in Q2 2019.